Korean Stock Flows

GC Biopharma (KRX: 006280)

녹십자 KOSPI Biotech & Pharma 의약품 제조업
Close (Oct 16, 2026)
₩127,600
+2.08%
Market cap
₩1T ($1.1B)
52-week range
₩105,900 – ₩183,800
P/E (12M fwd) · P/B · Div yield
19.42 · 1.20 · 1.18%
trailing – · consensus of 4 analysts

Who is buying GC Biopharma?

Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net sold ₩0.0bn ($0M) of GC Biopharma, the 468th largest foreign net sale among 832 KOSPI stocks. Institutions net bought ₩1.8bn ($1M) and retail investors net sold ₩3.0bn ($2M) over the same window. Foreigners were net buyers on 11 of the 20 sessions.

Foreign investors hold 23.65% of GC Biopharma's listed shares (KRX ownership data as of Oct 16, 2026), down from 23.83% twenty sessions earlier and 21.09% a year ago.

The stock closed at ₩127,600 on Oct 16, 2026: +0.79% over 20 sessions, -19.75% year-to-date, -1.39% over one year. The 52-week range is ₩105,900 – ₩183,800.

At ₩127,600 the stock trades at 19.42× 12-month-forward consensus earnings (4 analysts), 30.68× on FY2027 estimates.

GC Biopharma share price, last 60 trading days (KRW)
134,294 126,865 119,435 112,006 Jul 16 Aug 31 Oct 16
Daily foreign investor net purchases, last 60 trading days
+2.4bn +1.2bn -1.2bn -2.4bn Jul 16 Aug 31 Oct 16
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-16 ₩127,600 +₩1.8bn ₩-0.1bn ₩-1.8bn
2026-10-15 ₩125,000 +₩0.2bn +₩0.7bn ₩-0.8bn
2026-10-14 ₩127,400 +₩0.2bn +₩0.1bn ₩-0.3bn
2026-10-13 ₩127,400 ₩-0.3bn +₩0.6bn ₩-0.2bn
2026-10-12 ₩128,100 ₩-0.4bn +₩0.5bn ₩-0.1bn
2026-10-08 ₩129,400 ₩-2.4bn +₩0.4bn +₩2.0bn
2026-10-07 ₩130,500 +₩0.4bn +₩0.0bn ₩-0.5bn
2026-10-06 ₩127,500 +₩0.7bn ₩-0.2bn ₩-0.5bn
2026-10-02 ₩125,800 ₩-1.0bn +₩0.3bn +₩0.8bn
2026-10-01 ₩129,300 +₩2.0bn +₩0.9bn ₩-3.0bn
2026-09-30 ₩123,000 +₩0.5bn ₩-0.1bn ₩-0.5bn
2026-09-29 ₩123,200 +₩0.4bn ₩-0.4bn +₩0.0bn
2026-09-28 ₩123,200 +₩0.2bn ₩-0.2bn ₩-0.0bn
2026-09-23 ₩123,300 +₩0.4bn ₩-0.2bn ₩-0.2bn
2026-09-22 ₩123,300 ₩-0.2bn ₩-0.3bn +₩0.5bn
2026-09-21 ₩125,700 +₩1.6bn +₩0.0bn ₩-1.6bn
2026-09-18 ₩122,400 ₩-2.1bn +₩0.4bn +₩0.7bn
2026-09-17 ₩122,700 ₩-0.3bn ₩-0.0bn +₩0.3bn
2026-09-16 ₩122,400 ₩-1.4bn ₩-0.2bn +₩1.6bn
2026-09-15 ₩124,900 ₩-0.3bn ₩-0.5bn +₩0.8bn
2026-09-14 ₩126,600 ₩-0.4bn +₩0.0bn +₩0.3bn
2026-09-11 ₩128,300 ₩-0.3bn +₩0.5bn ₩-0.2bn
2026-09-10 ₩130,100 +₩0.4bn +₩0.7bn ₩-1.1bn
2026-09-09 ₩127,400 +₩0.3bn ₩-0.3bn +₩0.1bn
2026-09-08 ₩127,000 +₩0.3bn ₩-0.3bn +₩0.0bn
2026-09-07 ₩127,300 ₩-1.0bn +₩0.3bn +₩0.6bn
2026-09-04 ₩127,600 ₩-0.3bn +₩0.3bn +₩0.0bn
2026-09-03 ₩127,000 ₩-0.8bn ₩-0.1bn +₩0.8bn
2026-09-02 ₩127,000 +₩0.3bn ₩-0.2bn ₩-0.2bn
2026-09-01 ₩128,100 +₩0.2bn ₩-0.3bn +₩0.1bn
2026-08-31 ₩129,100 ₩-0.3bn ₩-0.1bn +₩0.4bn
2026-08-28 ₩130,500 +₩0.2bn +₩0.7bn ₩-0.8bn
2026-08-27 ₩127,100 ₩-1.2bn +₩0.2bn +₩1.0bn
2026-08-26 ₩130,500 +₩0.8bn +₩0.6bn ₩-1.4bn
2026-08-25 ₩126,300 ₩-0.8bn +₩0.3bn +₩0.5bn
2026-08-24 ₩130,300 +₩0.8bn +₩1.8bn ₩-2.6bn
2026-08-21 ₩122,100 +₩1.2bn ₩-0.0bn ₩-1.1bn
2026-08-20 ₩125,400 ₩-2.4bn ₩-0.7bn +₩3.1bn
2026-08-19 ₩121,000 ₩-0.1bn ₩-0.2bn +₩0.3bn
2026-08-18 ₩121,800 ₩-1.2bn ₩-1.6bn +₩2.8bn
2026-08-14 ₩129,200 ₩-0.2bn ₩-0.2bn +₩0.4bn
2026-08-13 ₩129,500 +₩1.0bn ₩-1.0bn +₩0.0bn
2026-08-12 ₩129,500 ₩-0.1bn ₩-0.2bn +₩0.4bn
2026-08-11 ₩132,700 +₩2.0bn ₩-0.4bn ₩-1.6bn
2026-08-10 ₩133,100 +₩1.8bn +₩0.1bn ₩-1.8bn
2026-08-07 ₩129,900 +₩0.8bn +₩0.6bn ₩-1.3bn
2026-08-06 ₩126,500 +₩1.2bn +₩0.4bn ₩-1.6bn
2026-08-05 ₩122,300 +₩1.0bn +₩0.1bn ₩-1.1bn
2026-08-04 ₩120,000 +₩2.3bn +₩0.3bn ₩-2.5bn
2026-08-03 ₩113,300 +₩0.2bn ₩-1.6bn +₩1.4bn
2026-07-31 ₩115,900 ₩-0.4bn ₩-0.3bn +₩0.7bn
2026-07-30 ₩114,200 +₩1.3bn +₩0.4bn ₩-1.7bn
2026-07-29 ₩113,200 ₩-0.4bn ₩-0.0bn ₩-1.6bn
2026-07-28 ₩120,600 ₩-0.4bn +₩0.3bn ₩-0.3bn
2026-07-27 ₩123,800 +₩0.2bn +₩0.4bn ₩-0.6bn
2026-07-24 ₩123,700 +₩1.2bn ₩-0.2bn ₩-1.0bn
2026-07-23 ₩123,100 +₩1.0bn +₩0.2bn ₩-1.3bn
2026-07-22 ₩118,700 +₩0.6bn ₩-0.8bn ₩-0.4bn
2026-07-21 ₩118,600 +₩0.6bn ₩-1.9bn ₩-0.3bn
2026-07-20 ₩119,600 ₩-1.2bn +₩0.5bn +₩0.1bn
2026-07-16 ₩122,800 +₩0.9bn +₩0.0bn ₩-0.9bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day +₩1.8bn +$1M ₩-0.1bn ₩-1.8bn
5 days +₩1.4bn +$1M +₩1.8bn ₩-3.3bn
20 days ₩-0.0bn $-0M +₩1.8bn ₩-3.0bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying GC Biopharma stock?

Over the last 5 sessions foreign investors net bought ₩1.4bn ($1M) of GC Biopharma; over 60 sessions they net bought ₩8.5bn ($6M); since Jan 1, 2026 they net bought ₩11.2bn ($8M). Over 20 sessions the stock is the 468th largest foreign net sale among 832 KOSPI stocks.

How much of GC Biopharma do foreign investors own?

Foreign investors own 23.65% of GC Biopharma's shares as of Oct 16, 2026, versus 21.09% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net bought ₩1.8bn ($1M) and retail investors net sold ₩3.0bn ($2M) of GC Biopharma. Institutions are on the other side of foreign selling.

Is GC Biopharma listed on KOSPI or KOSDAQ?

GC Biopharma (녹십자) trades on KOSPI under KRX code 006280 in the Biotech & Pharma group, with a market capitalization of ₩1T ($1.1B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩1.6T ($1.2B) – ₩34bn ($26M) -₩20bn (-$15M)
2024 ₩1.7T ($1.2B) +3.30% ₩32bn ($24M) -₩43bn (-$32M)
2025 ₩2.0T ($1.5B) +18.50% ₩69bn ($51M) -₩30bn (-$22M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.

← All foreign investor flows